Drug Trial Radar · NCT07886476
IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Jan 31, 2027
Study completion Feb 28, 2028
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Part 1 is a Single Ascending Dose (SAD) study, and Part 2 is a Multiple Ascending Dose (MAD) study
Conditions
- IgA Nephropathy (IgAN)
Interventions
IBI3034Drug
IBI3034,SC/IV,corresponding dose regimen according to study design
PlaceboDrug
Matching placebo of IBI3034,SC/ IV ,corresponding dose regimen according to study design
TelitaciceptDrug
Telitacicept 240 mg SC QW × 24 doses (Weeks 0-24).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Incidence of adverse events (AEs) and serious adverse events (SAEs) following a single dose of IBI3034 in healthy participants(Part 1)Time frame: through study completion,an average of 169 days
- Safety: Incidence of AEs and SAEs following multiple doses of IBI3034 in participants with primary IgA nephropathy(Part 2)Time frame: through study completion,an average of 252 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.